Raymond James & Associates’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-796
| Closed | -$13.8K | – | 3919 |
|
|
2024
Q1 | $13.8K | Buy |
796
+12
| +2% | +$208 | ﹤0.01% | 3848 |
|
|
2023
Q4 | $10K | Sell |
784
-6,802
| -90% | -$87.2K | ﹤0.01% | 3739 |
|
|
2023
Q3 | $281K | Buy |
7,586
+92
| +1% | +$3.4K | ﹤0.01% | 3236 |
|
|
2023
Q2 | $302K | Sell |
7,494
-62
| -0.8% | -$2.5K | ﹤0.01% | 3229 |
|
|
2023
Q1 | $548K | Buy |
7,556
+287
| +4% | +$20.8K | ﹤0.01% | 2847 |
|
|
2022
Q4 | $596K | Sell |
7,269
-105
| -1% | -$8.61K | ﹤0.01% | 2767 |
|
|
2022
Q3 | $697K | Buy |
7,374
+4,765
| +183% | +$450K | ﹤0.01% | 2609 |
|
|
2022
Q2 | $508K | Buy |
+2,609
| New | +$508K | ﹤0.01% | 2895 |
|
|
2020
Q2 | – | Sell |
-951
| Closed | -$202K | – | 3403 |
|
|
2020
Q1 | $202K | Buy |
951
+104
| +12% | +$22.1K | ﹤0.01% | 3024 |
|
|
2019
Q4 | $349K | Buy |
847
+38
| +5% | +$15.7K | ﹤0.01% | 2968 |
|
|
2019
Q3 | $286K | Sell |
809
-9
| -1% | -$3.18K | ﹤0.01% | 3017 |
|
|
2019
Q2 | $411K | Sell |
818
-218
| -21% | -$110K | ﹤0.01% | 2800 |
|
|
2019
Q1 | $1.03M | Buy |
1,036
+7
| +0.7% | +$6.96K | ﹤0.01% | 2177 |
|
|
2018
Q4 | $893K | Sell |
1,029
-12
| -1% | -$10.4K | ﹤0.01% | 2150 |
|
|
2018
Q3 | $1.08M | Sell |
1,041
-15
| -1% | -$15.5K | ﹤0.01% | 2205 |
|
|
2018
Q2 | $970K | Sell |
1,056
-61
| -5% | -$56K | ﹤0.01% | 2239 |
|
|
2018
Q1 | $1.09M | Buy |
1,117
+104
| +10% | +$101K | ﹤0.01% | 2076 |
|
|
2017
Q4 | $458K | Buy |
1,013
+69
| +7% | +$31.2K | ﹤0.01% | 2574 |
|
|
2017
Q3 | $391K | Hold |
944
| – | – | ﹤0.01% | 2614 |
|
|
2017
Q2 | $330K | Buy |
944
+132
| +16% | +$46.1K | ﹤0.01% | 2648 |
|
|
2017
Q1 | $417K | Buy |
812
+91
| +13% | +$46.7K | ﹤0.01% | 2488 |
|
|
2016
Q4 | $256K | Buy |
+721
| New | +$256K | ﹤0.01% | 2724 |
|